Shopping Cart
- Remove All
![TargetMol](https://www.targetmol.com/storage/error/oops.webp)
Your shopping cart is currently empty
Pack Size | Price | Availability | Quantity |
---|---|---|---|
1 mg | Inquiry | Backorder | |
5 mg | Inquiry | Backorder |
Description | Vixtimotamab (AMV-564; TandAb T564), a bispecific tetravalent tandem diabody (TandAb), selectively engages human CD33 and CD3 antigens. It is utilized in research on acute myeloid leukemia (AML) [1]. |
In vitro | Vixtimotamab (TandAb T564; 24 h) induces CD25 and CD69 with respective EC50 values of 1 pM and 2 pM [1]. Additionally, Vixtimotamab (TandAb T564; 4 days) prompts T-cell proliferation within PBMCs, having an EC50 of 3 pM [1]. Furthermore, Vixtimotamab (TandAb T564; 25 pM, 48 h) exhibits cytotoxicity against HL-60 and KG-1a cells [1]. |
In vivo | Vixtimotamab (TandAb T564; 0.1-10 μg/mouse, i.v.; 5 days) demonstrated a dose-dependent delay in tumor growth in a prophylactic HL-60 xenografted NOD/scid mouse model [1]. Additionally, vixtimotamab (TandAb T564; 50 μg/mouse/d, i.v.; 7 days) significantly inhibited tumor growth in an established HL-60 xenografted NOD/scid mouse model [1]. |
Alias | TandAb T564, AMV-564 |
Cas No. |
Storage |
Copyright © 2015-2024 TargetMol Chemicals Inc. All Rights Reserved.